Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

• Register: ClinicalTrials.gov
• Last refreshed on: 18 September 2023
• Main ID: NCT03774446
• Date of registration: 06/11/2018
• Prospective Registration: No
• Primary sponsor: Cedars-Sinai Medical Center
• Public title: Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
• Scientific title: A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
• Date of first enrolment: November 2, 2018
• Target sample size: 13
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/ct2/show/NCT03774446
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

United States

Contacts

• Name: Vivian Hwe

• Name: Ning-Ai Liu, MD, PhD
• Affiliation: Cedars-Sinai Medical Center

• Name: Vivian Hwe

• Name: Shlomo Melmed, MD
• Affiliation: Cedars-Sinai Medical Center

Key inclusion & exclusion criteria

Inclusion Criteria:

- Male and female patients at least 18 years old

- Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH)
production:

- Persistent hypercortisolemia established by two consecutive 24-hour UFC
assessment =1.5× the upper limit of normal

- Normal or elevated ACTH levels

- Pituitary adenoma (>1 cm) on MRI or inferior petrosal sinus sampling (IPSS)
central to peripheral ACTH gradient >2 at baseline and >3 after CRH stimulation

- Recurrent or persistent CD defined as pathologically confirmed resected pituitary
ACTH-secreting tumor or IPSS central to peripheral ACTH gradient >2 at baseline
and >3 after CRH stimulation, and 24h-UFC >ULN beyond post-surgical week 6

- Patients on medical treatment for Cushing disease. The following washout periods must
be completed before screening assessments are performed:

- Inhibitors of steroidogenesis: metyrapone, ketoconazole: 2 weeks;
Levoketoconazole: 3 weeks; osilodrostat: 6 weeks

- Somatostatin receptor ligand pasireotide: short-acting, 2 weeks; long-acting, 4
weeks

- Progesterone receptor antagonist mifepristone: 2 weeks

- Dopamine agonist cabergoline: 4 weeks

- Patients treated with CYP3A or CYP2B6 strong inducers or inhibitors, including
those listed below. Required washout time varies between drugs; minimum 5-6 times
the half-life of the drug.

- Strong CYP3A inducers: apalutamide, carbamazepine, enzalutamide, mitotane,
phenytoin, rifampin, St. John's wort

- Moderate CYP3A inducers: bosentan, efavirenz, etravirine, phenobarbital,
primidone

- Weak CYP3A inducers: armodafinil, modafinil, rufinamide

- Strong CYP2B6 inducer: carbamazepine

- Moderate CYP2B6 inducers: efavirenz, rifampin

- Weak CYP2B6 inducers: nevirapine, ritonavir

- Strong CYP3A inhibitors: boceprevir, cobicistat, danoprevir and ritonavir,
elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir,
itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and
ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir,
saquinavir and ritonavir, telaprevir, tipranavir and ritonavir,
telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib,
nefazodone, nelfinavir.

- Moderate CYP3A inhibitors: aprepitant, ciprofloxacin, conivaptan,
crizotinib, cyclosporine, diltiazem, dronedarone, erythromycin, fluconazole,
fluvoxamine, imatinib, verapamil

- Strong CYP2B6 inhibitor: ticlopidine

Exclusion criteria:

- Patients with compromised visual fields, and not stable for at least 6 months

- Patients with abutment or compression of the optic chiasm on MRI and normal visual
fields

- Patients with Cushing's syndrome due to non-pituitary ACTH secretion

- Patients with hypercortisolism secondary to adrenal tumors or nodular (primary)
bilateral adrenal hyperplasia

- Patients who have a known inherited syndrome as the cause for hormone over secretion
(i.e., Carney Complex, McCune-Albright syndrome, Multiple endocrine neoplasia (MEN) 1

- Patients with a diagnosis of glucocorticoid-remedial aldosteronism (GRA)

- Patients with cyclic Cushing's syndrome defined by any measurement of UFC over the
previous 1 months within normal range

- Patients with pseudo-Cushing's syndrome, i.e., non-autonomous hypercortisolism due to
overactivation of the hypothalamic-pituitary-adrenal (HPA) axis in uncontrolled
depression, anxiety, obsessive compulsive disorder, morbid obesity, alcoholism, and
uncontrolled diabetes mellitus

- Patients who have undergone major surgery within 1 month prior to screening

- Patients with serum K+< 3.5 while on replacement treatment

- Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C >8%

- Patients who have clinically significant impairment in cardiovascular function or are
at risk thereof, as evidenced by congestive heart failure (NYHA Class III or IV),
unstable angina, sustained ventricular tachycardia, clinically significant
bradycardia, high grade atrioventricular (AV) block, history of acute MI less than one
year prior to study entry

- Patients with liver disease or history of liver disease such as cirrhosis, chronic
active hepatitis B and C, or chronic persistent hepatitis, or patients with abnormal
alanine transferase (ALT) or aspartate aminotransferase (AST) at screening or patients
with advanced liver fibrosis (=10 kPa) on elastography at screening

- Patients with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2

- Patients not biochemically euthyroid

- Patients who have any current or prior medical condition that can interfere with the
conduct of the study or the evaluation of its results, such as

- History of immunocompromise, including a positive HIV test result (ELISA and
Western blot). An HIV test will not be required, however, previous medical
history will be reviewed

- Presence of active or suspected acute or chronic uncontrolled infection

- History of, or current alcohol misuse/abuse in the 12 month period prior to
screening

- Female patients who are pregnant or lactating, or are of childbearing potential and
not practicing a medically acceptable method of birth control. If a woman is
participating in the trial then one form of contraception is sufficient (pill or
diaphragm) and the partner should use a condom. If oral contraception is used in
addition to condoms, the patient must have been practicing this method for at least
two months prior to screening and must agree to continue the oral contraceptive
throughout the course of the study and for 3 months after the study has ended. Male
patients who are sexually active are required to use condoms during the study and for
three months afterwards as a precautionary measure (available data do not suggest any
increased reproductive risk with the study drugs)

- Patients who have participated in any clinical investigation with an investigational
drug within 1 month prior to screening or patients who have previously been treated
with seliciclib

- Patients with any ongoing or lik


Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Cushing Disease

Intervention(s)

Drug: Seliciclib

Primary Outcome(s)

Number of participants with UFC above the upper limit of normal (ULN) but reduced by =50% from baseline at study completion [Time Frame: 4 weeks]

Number of participants with a normalized 24-hour urinary free cortisol (UFC) at study completion [Time Frame: 4 weeks]

Secondary Outcome(s)

Change in quality of life measured using the CushingQOL questionnaire [Time Frame: Baseline and week 4]

Change in tumor size on pituitary MRI [Time Frame: Baseline and week 4]

Glycated hemoglobin (HbA1c) [Time Frame: Baseline and week 4]

Change on visual field exam [Time Frame: Baseline and week 4]

Salivary cortisol [Time Frame: Baseline and week 4]

Plasma adrenocorticotrophic hormone [Time Frame: Baseline and week 4]

Number of treatment-emergent adverse events graded using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 4.0 [Time Frame: Baseline and week 4]

Serum cortisol [Time Frame: Baseline and week 4]

Blood pressure [Time Frame: Baseline and week 4]

Fasting blood glucose [Time Frame: Baseline and week 4]

Weight and height to report body mass index (BMI) in kg/m^2 [Time Frame: Baseline and week 4]

Secondary ID(s)

FD-R-6106

Pro52406

Source(s) of Monetary Support

Please refer to primary and secondary sponsors